Catena® for the treatment of Duchenne Muscular Dystrophy

The DELOS (DuchEnne Muscular Dystrophy Long-term IdebenOne Study) study is a double-blind, randomized, placebo-controlled clinical trial evaluating the safety, tolerability and efficacy of one dose of Catena®(idebenone, 900 mg/day) compared to placebo. For more information about DELOS, please visit www.clinicaltrials.gov (Identifier NCT01027884) or www.mda.org.

Austria

Gottfried v. Preyer'sches Kinderspital, Vienna
Principal investigator: Dr Günther Bernert
Phone: +43 1 60 113 1201; Email: guenther.bernert@wienkav.at

Belgium

University Hospital Leuven, Leuven
Principal investigator: Prof Gunnar Buyse
Contact person: Eva Misbaer
Phone: +32 1 63 43 843; Email: eva.misbaer@uzleuven.be

France

Université Pierre et Marie curie VI, Paris
Principal investigator: Prof Thomas Voit
Contact person: Dr Valérie Doppler
Phone: +33 1 42 16 58 73; Email: v.doppler@insitut-myologie.org

Germany

Universitätsklinikum Essen, Essen
Principal investigator: Prof Ulrike Schara
Contact person: Bärbel Leiendecker
Phone: +49 201 723 2508; Email: baerbel.leiendecker@uk-essen.de

The Netherlands

Leiden University Medical Center (LUMC), Leiden
Principal investigator: Prof Jan Verschuuren
Contact person: Dr Straathof
Phone: +31 71 52 621 97; Email: c.s.m.straathof@lumc.nl

Sweden

Karolinska Universitetssjukhuset, Stockholm
Principal investigator: Prof Thomas Sejersen
Contact person: Erika Trulsson; Email: erika.trulsson@karolinska.se

Switzerland

Centre Hospitalier Universitaire Vaudois, Lausanne
Principal investigator: Dr Pierre-Yves Jeannet
Contact person: Dr Clemens Blötzer
Phone: +41 21 31 43 572; Email: clemens.bloetzer@chuv.ch

United States of America

The Children's Hospital of Philadelphia, Philadelphia, PA
Principal investigator: Richard S. Finkel, M.D
Contact person: Michele Toms
Phone: +1 215 590 7727; Email: toms@email.chop.edu

For a more detailed list of the DELOS study centers, please click here.